Base-Edited HSPCs therapy (Cimeio Therapeutics)

N/A

Report date: 2025/05/20 17:40:10

Base Information

Drug NameBase-Edited HSPCs therapy (Cimeio Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapy > Gene editing > Base editingCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsStem cell replacements

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCimeio Therapeutics AG

China Registration ClassN/A

Develop Information

Active CompaniesCimeio Therapeutics AG

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A